Koyama Yoichi, Kawai Saori, Uenaka Natsuki, Okazaki Miki, Asaoka Mariko, Teraoka Saeko, Ueda A I, Miyahara Kana, Kawate Takahiko, Kaise Hiroshi, Yamada Kimito, Ishikawa Takashi
Department of Breast Oncology and Surgery, Tokyo Medical University, Tokyo, Japan.
Department of Breast Oncology and Surgery, Tokyo Medical University Hachioji Medical Centre, Tokyo, Japan.
Cancer Diagn Progn. 2021 Nov 3;1(5):435-441. doi: 10.21873/cdp.10058. eCollection 2021 Nov-Dec.
BACKGROUND/AIM: To investigate the utility of peripheral blood biomarkers - absolute lymphocyte count (ALC), neutrophil-to-lymphocyte ratio (NLR), and platelet-to-lymphocyte ratio (PLR) - for predicting outcomes in eribulin-treated patients with metastatic human epidermal growth factor receptor type 2 (HER2)-negative breast cancer.
ALC, NLR, and PLR were retrospectively obtained from pre-treatment blood sampling results of 120 patients and stratified according to means. Univariate and multivariate analyses were performed to investigate the association of clinicopathological factors, including these values, with overall survival (OS) and progression-free survival (PFS).
The ALC, NLR, and PLR cut-off points were 1,285/μl, 3.3, and 235, respectively. No biomarkers were associated with PFS. However, univariate analysis showed ALC (p=0.044) and PLR (p=0.044) to be significantly associated with OS.
ALC and PLR can predict eribulin efficacy in terms of OS, reflecting the antitumour immune response in the microenvironment and indicating eribulin's effectiveness.
背景/目的：探讨外周血生物标志物——绝对淋巴细胞计数（ALC）、中性粒细胞与淋巴细胞比值（NLR）和血小板与淋巴细胞比值（PLR）——对预测接受艾日布林治疗的转移性人表皮生长因子受体2（HER2）阴性乳腺癌患者预后的作用。
回顾性获取120例患者治疗前血液样本检测结果中的ALC、NLR和PLR，并根据均值进行分层。进行单因素和多因素分析，以研究包括这些指标在内的临床病理因素与总生存期（OS）和无进展生存期（PFS）之间的关联。
ALC、NLR和PLR的切点分别为1285/μl、3.3和235。没有生物标志物与PFS相关。然而，单因素分析显示ALC（p=0.044）和PLR（p=0.044）与OS显著相关。
ALC和PLR可根据OS预测艾日布林疗效，反映微环境中的抗肿瘤免疫反应，表明艾日布林的有效性。
